Blog | Page 7 of 14 | Pharma Lesson

Regulatory Affairs and Compliance

Biowaivers for Fixed-Dose Combination (FDC) Drug Products
ByPharma Lesson April 4, 2025April 4, 2025 Reading Time: 2 minutes

Fixed-dose combination (FDC) drug products present unique challenges in biowaiver assessments, as they involve multiple active pharmaceutical ingredients (APIs) with different physicochemical properties and release characteristics. Regulatory guidelines (USFDA, EMA, WHO) provide biowaiver provisions, but their applicability depends on several factors, such as API solubility, permeability, formulation type, and release mechanisms. Key Considerations for Biowaivers…

Read More Biowaivers for Fixed-Dose Combination (FDC) Drug Products
Formulation

Impact of Polymer Quantity Adjustment in Sustained-Release Formulations
ByPharma Lesson April 4, 2025April 4, 2025 Reading Time: 2 minutes

Adjusting polymer content in a sustained-release dosage form requires a systematic approach to maintain the desired drug release profile while ensuring manufacturability and regulatory compliance. Role of the Polymer in Drug Release Control Polymers in sustained-release formulations act as matrix formers, coating agents, or swelling/erosion regulators. For example, HPMC, Ethylcellulose (EC), and Polyethylene Oxide (PEO)…

Read More Impact of Polymer Quantity Adjustment in Sustained-Release Formulations
Regulatory Affairs and Compliance

CBE-30 vs. PAS Filing for Topical Products
ByPharma Lesson April 4, 2025April 4, 2025 Reading Time: 2 minutes

Regulatory compliance is a critical aspect of pharmaceutical product lifecycle management. When making post-approval changes in topical formulations, selecting the appropriate FDA submission pathway—CBE-30 (Changes Being Effected in 30 Days) or PAS (Prior Approval Supplement)—ensures compliance while maintaining business continuity. Understanding when to file CBE-30 vs. PAS can significantly impact timelines, regulatory approvals, and market…

Read More CBE-30 vs. PAS Filing for Topical Products
Formulation

Challenges in Topical Product Development
ByPharma Lesson March 29, 2025March 29, 2025 Reading Time: 1 minute

Formulating effective topical products is a complex process that requires balancing efficacy, stability, and patient compliance. Here are some common challenges and practical solutions: Poor Drug Penetration Instability of Active Ingredients Phase Separation in Emulsions Grittiness or Texture Issues Preservative System Failure Inconsistent Spreadability & Feel Successful topical formulations require a deep understanding of formulation…

Read More Challenges in Topical Product Development
Quality by Design

The Role of Quality by Design (QbD) in CMC
ByPharma Lesson March 29, 2025March 29, 2025 Reading Time: 1 minute

In the evolving pharmaceutical landscape, Quality by Design (QbD) has transformed the Chemistry, Manufacturing, and Controls (CMC) framework, shifting the focus from mere compliance to science- and risk-based drug development. Why QbD Matters in CMC? Traditionally, regulatory submissions relied on empirical data with limited flexibility. QbD, however, ensures a deep understanding of product and process…

Read More The Role of Quality by Design (QbD) in CMC
Formulation | Quality by Design

Quality by Design (QbD) in Topical Formulations
ByPharma Lesson March 29, 2025March 29, 2025 Reading Time: 2 minutes

In topical pharmaceutical development, achieving batch-to-batch consistency, therapeutic efficacy, and regulatory compliance requires a Quality by Design (QbD) framework. A well-defined design space based on Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs) ensures an optimized, scalable, and reproducible formulation. Identifying CMAs in Topical Formulations API Attributes: Excipient Functionality: Defining…

Read More Quality by Design (QbD) in Topical Formulations